IL122359A - Stable gel formulation for topical treatment of skin conditions (acne, psoriasis) comprising ethyl-6-[2-(4,4)-dimethylthiochroman-6-yl] nicotinate in a pharmaceutical carrier and a method for its preparation - Google Patents

Stable gel formulation for topical treatment of skin conditions (acne, psoriasis) comprising ethyl-6-[2-(4,4)-dimethylthiochroman-6-yl] nicotinate in a pharmaceutical carrier and a method for its preparation

Info

Publication number
IL122359A
IL122359A IL12235995A IL12235995A IL122359A IL 122359 A IL122359 A IL 122359A IL 12235995 A IL12235995 A IL 12235995A IL 12235995 A IL12235995 A IL 12235995A IL 122359 A IL122359 A IL 122359A
Authority
IL
Israel
Prior art keywords
acne
psoriasis
gel formulation
dimethylthiochroman
nicotinate
Prior art date
Application number
IL12235995A
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IL122359A publication Critical patent/IL122359A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL12235995A 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions (acne, psoriasis) comprising ethyl-6-[2-(4,4)-dimethylthiochroman-6-yl] nicotinate in a pharmaceutical carrier and a method for its preparation IL122359A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25509494A 1994-06-07 1994-06-07
IL11404995A IL114049A (en) 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions (acne, psoriasis) containing active agent and non-aqueous vehicles for control or release of active agent from the gel

Publications (1)

Publication Number Publication Date
IL122359A true IL122359A (en) 2001-08-26

Family

ID=22966815

Family Applications (3)

Application Number Title Priority Date Filing Date
IL12235995A IL122359A (en) 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions (acne, psoriasis) comprising ethyl-6-[2-(4,4)-dimethylthiochroman-6-yl] nicotinate in a pharmaceutical carrier and a method for its preparation
IL11404995A IL114049A (en) 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions (acne, psoriasis) containing active agent and non-aqueous vehicles for control or release of active agent from the gel
IL12235895A IL122358A (en) 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions (acne psoriasis) containing active agent and non-aqueous vehicles for control of solubility

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL11404995A IL114049A (en) 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions (acne, psoriasis) containing active agent and non-aqueous vehicles for control or release of active agent from the gel
IL12235895A IL122358A (en) 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions (acne psoriasis) containing active agent and non-aqueous vehicles for control of solubility

Country Status (13)

Country Link
US (2) US5914334A (pt)
EP (2) EP1147778B1 (pt)
AT (2) ATE336263T1 (pt)
AU (1) AU693905B2 (pt)
CA (1) CA2191773C (pt)
DE (2) DE69526344T2 (pt)
DK (1) DK1147778T3 (pt)
ES (2) ES2173958T3 (pt)
IL (3) IL122359A (pt)
PT (1) PT1147778E (pt)
TW (1) TW379143B (pt)
WO (1) WO1995033489A1 (pt)
ZA (1) ZA954599B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
IT1288708B1 (it) * 1996-10-17 1998-09-23 Achille Sandoli Composizione farmaceutica comprendente trometamina per il trattamento per via topica dell'acne vulgaris.
CA2282682C (en) * 1997-02-20 2008-08-19 Allergan Sales, Inc. Tazarotene and corticosteroid treatment for psoriasis
ES2247699T3 (es) * 1997-06-11 2006-03-01 Allergan, Inc. Tratamiento de la psoriasis a base de tazaroteno y fototerapia.
AU6787998A (en) * 1998-03-30 1999-10-18 Procter & Gamble Company, The Skin care compositions
US20020160995A1 (en) * 1998-08-03 2002-10-31 Easterling W. Jerry Medication and method for remediating existing scars through transdermal, topical delivery of calcium channel blockers
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
CA2406064C (en) * 2000-04-26 2011-03-15 Watson Pharmaceuticals, Inc. Minimizing adverse experience associated with oxybutynin therapy
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
FR2830449B1 (fr) * 2001-10-05 2004-04-23 Fabre Pierre Dermo Cosmetique Utilisation du tazarotene pour la preparation d'un vernis a ongles pour le traitement et/ou la prevention du psoriasis et un vernis a ongles le contenant
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US20060084685A1 (en) * 2002-05-28 2006-04-20 Altana Pharma Ag Ophthalmological use of roflumilast for the treatment of diseases of the eye
US20040018220A1 (en) * 2002-07-26 2004-01-29 Chiou Consulting, Inc. Aqueous compositions for facial cosmetics
CA2510038A1 (en) * 2002-12-17 2004-07-01 Galderma Research & Development, S.N.C. Process for the chemical stabilization of a solubilized retinoid in a solvent using a base
FR2848451B1 (fr) * 2002-12-17 2007-01-12 Galderma Res & Dev Procede de stabilisation chimique d'un retinoide solubilise et composition aqueuse obtenue selon le procede comprenant au moins un retinoide sous forme salifiee
JP2008540514A (ja) 2005-05-10 2008-11-20 ダーミプソル リミテッド 過剰増殖表皮疾患の治療用組成物及び方法
AR054805A1 (es) * 2005-06-29 2007-07-18 Stiefel Laboratories Composiciones topicas para el tratamiento de la piel
US20070060620A1 (en) * 2005-09-09 2007-03-15 John Sefton Use of RAR retinoid agonists to increase sperm count and sperm mobility in males
JP2009510087A (ja) * 2005-09-30 2009-03-12 オーエムピー インコーポレーテッド 安定アスコルビン酸組成物
US20070269534A1 (en) * 2006-02-02 2007-11-22 Ramirez Jose E Methods of treating skin to enhance therapeutic treatment thereof
US20070178058A1 (en) * 2006-02-02 2007-08-02 Ramirez Jose E Methods of using stable ascorbic acid compositions
WO2007092312A2 (en) * 2006-02-03 2007-08-16 Stiefel Laboratories, Inc. Topical skin treating compositions
WO2008007224A2 (en) 2006-03-31 2008-01-17 Stiefel Research Australia Pty Ltd Foamable suspension gel
MXPA06008988A (es) * 2006-08-08 2008-02-07 Fernando Ahumada Ayala Preparaciones topicas antiacne que contienen retinoide (tazaroteno o adapaleno), antibiotico (fosfato de clindamicina) y/o queratolitico (peroxido de bonzoilo en microesponjas).
US20080299182A1 (en) * 2007-03-01 2008-12-04 Shuyuan Zhang Methods and formulations for topical gene therapy
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
US20110117182A1 (en) * 2009-07-30 2011-05-19 Allergan, Inc. Combination of dapsone with other anti-acne agents
NZ602120A (en) 2010-03-12 2015-02-27 Monsanto Technology Llc Agrochemical gel compositions
EP2624817A1 (en) * 2010-10-08 2013-08-14 Helperby Therapeutics Limited Novel composition
RU2016117298A (ru) 2013-10-31 2017-12-06 Сан Фармасьютикал Индастриз Лимитед Фармацевтические композиции на основе ацитретина для местного применения
US11311529B2 (en) * 2018-11-08 2022-04-26 Varsona Therapeutics, Inc. Topical formulations of 5-α-reductase inhibitors and uses thereof
US11311556B2 (en) 2020-05-13 2022-04-26 Varsona Therapeutics, Inc. Topical dutasteride emulsions for treating endocrine therapy-induced alopecia
KR20230039979A (ko) * 2021-09-15 2023-03-22 서울대학교산학협력단 아토피 피부염 예방 또는 치료용 겔 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3934028A (en) * 1974-04-22 1976-01-20 The Regents Of The University Of California Acne and psoriasis treatment with retinoic acid analogs
US4895727A (en) * 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US4810804A (en) * 1987-03-26 1989-03-07 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid-like activity
WO1990014833A1 (en) * 1989-06-07 1990-12-13 Bazzano Gail S Slow release vehicles for minimizing skin irritancy of topical compositions
AU670777B2 (en) * 1992-04-16 1996-08-01 Ortho Pharmaceutical Corporation Aqueous gel vehicles for retinoids
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
ES2247699T3 (es) * 1997-06-11 2006-03-01 Allergan, Inc. Tratamiento de la psoriasis a base de tazaroteno y fototerapia.
US6017938A (en) * 1998-07-28 2000-01-25 Bershad; Susan Short contact treatment for acne
US6114348A (en) * 1999-03-10 2000-09-05 Weber; Paul J. Method of treating warts using tazarotene

Also Published As

Publication number Publication date
DE69535184D1 (de) 2006-09-28
ES2269296T3 (es) 2007-04-01
IL114049A (en) 2000-08-31
US5914334A (en) 1999-06-22
DE69526344T2 (de) 2002-11-07
DE69526344D1 (de) 2002-05-16
ATE336263T1 (de) 2006-09-15
DK1147778T3 (da) 2006-12-18
DE69535184T2 (de) 2007-08-23
AU693905B2 (en) 1998-07-09
IL114049A0 (en) 1995-10-31
CA2191773A1 (en) 1995-12-14
CA2191773C (en) 2004-08-10
IL122358A (en) 2001-01-28
EP1147778A1 (en) 2001-10-24
PT1147778E (pt) 2006-12-29
TW379143B (en) 2000-01-11
AU2821895A (en) 1996-01-04
EP1147778B1 (en) 2006-08-16
US6258830B1 (en) 2001-07-10
ES2173958T3 (es) 2002-11-01
ZA954599B (en) 1996-01-26
WO1995033489A1 (en) 1995-12-14
EP0764032A1 (en) 1997-03-26
ATE215836T1 (de) 2002-04-15
EP0764032B1 (en) 2002-04-10

Similar Documents

Publication Publication Date Title
IL122359A (en) Stable gel formulation for topical treatment of skin conditions (acne, psoriasis) comprising ethyl-6-[2-(4,4)-dimethylthiochroman-6-yl] nicotinate in a pharmaceutical carrier and a method for its preparation
IL94490A0 (en) Stable,cosmetically acceptable topical gel formulation and method of treatment for acne
BR9607128A (pt) Emulsão de aplicação tópica aperfeiçoada para carregar ácido ascórbico e ingredientes ativos solúveis em água e cápsula mole de getatina
WO1996012498A3 (en) Dermatological compositions containing benzoyl peroxide and a compound reducing skin irritation
ATE332687T1 (de) Liponsäure in topischen mittel
FR2728793B1 (pt)
IE940583L (en) Topical antimicrobial pharmaceutical compositions
FR2755852B1 (fr) Utilisation d'un alkylether de glycerol dans une composition cosmetique et/ou dermatologique comme actif pour le traitement de la seborrhee et de l'acne
MY135988A (en) Additive for improving the water resistance of cosmetic or dermatological formulations
WO2001028491A3 (en) Method and composition for the treatment of dermatologic diseases
WO1997001343A3 (fr) Utilisation comme substances therapeutiquement actives ou produits cosmetiques des sophorolipides, en particulier pour le traitement de la peau
CA2291144A1 (en) Topical treatment of psoriasis using neutralizing antibodies to il-8
EP0766960A4 (en) PREPARATIONS FOR EXTERNAL USE FOR THE TREATMENT OF DERMATOS
CA2157142A1 (en) Treatment of diseases caused by sebaceous gland disorders
CA2190303A1 (en) Pharmaceutical composition, method and device for preventing or treating dry eye or disease caused therefrom
CA2099188A1 (en) Use of a cosmetic composition
FR2815869B1 (fr) Utilisation de microcapsules thermostabilisatrices pour ameliorer l'activite ou la penetration de principes actifs cosmetiques ou pharmaceutiques
ES2137125A1 (es) La utilizacion de la sal de zinc del acido glicirretico en preparados contra el acne y las composiciones que contienen dicha sal.
GB2210789A (en) Topical application for skin care
BR9711649A (pt) Processo e agente para a modelagem permanente de fibras de queratina
DE59610213D1 (de) Gegen Akne und entzündete Comedonen wirksame Wirkstoffkombinationen
ATE168004T1 (de) Juckreizstillendes mittel
CA2126704A1 (en) Dermatological Compositions and Methods for the Treatment of Skin Therewith
IL136342A0 (en) Formulation for topical treatment of skin infections
RU99114479A (ru) Способ лечения раневого процесса кожи век

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
EXP Patent expired